×
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
NASDAQ:OSUR

OraSure Technologies Stock Forecast, Price & News

$2.79
-0.10 (-3.46%)
(As of 06/28/2022 04:00 PM ET)
Add
Compare
Today's Range
$2.77
$2.95
50-Day Range
$2.72
$6.80
52-Week Range
$2.62
$13.57
Volume
881,407 shs
Average Volume
925,302 shs
Market Capitalization
$202.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.17
30 days | 90 days | 365 days | Advanced Chart

Receive OSUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OraSure Technologies and its competitors with MarketBeat's FREE daily newsletter.

OSUR Stock Forecast (MarketRank)

Overall MarketRank

2.21 out of 5 stars

Medical Sector

370th out of 1,433 stocks

Surgical & Medical Instruments Industry

45th out of 137 stocks

Analyst Opinion: 3.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
OraSure Technologies logo

About OraSure Technologies (NASDAQ:OSUR)

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.

OSUR Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:OSUR
CUSIP
68554V10
Employees
785
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
6/28/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$12.17
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+336.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.66666666666667
Research Coverage
3 Analysts

Profitability

Net Income
$-23 million
Pretax Margin
-14.67%

Debt

Sales & Book Value

Annual Sales
$233.67 million
Book Value
$5.28 per share

Miscellaneous

Free Float
70,862,000
Market Cap
$202.15 million
Optionable
Optionable
Beta
-0.24














OraSure Technologies Frequently Asked Questions

Should I buy or sell OraSure Technologies stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" OraSure Technologies stock.
View analyst ratings for OraSure Technologies
or view top-rated stocks.

What is OraSure Technologies' stock price forecast for 2022?

3 brokerages have issued twelve-month price targets for OraSure Technologies' shares. Their OSUR stock forecasts range from $10.00 to $14.00. On average, they predict OraSure Technologies' share price to reach $12.17 in the next twelve months. This suggests a possible upside of 336.1% from the stock's current price.
View analysts' price targets for OraSure Technologies
or view top-rated stocks among Wall Street analysts.

How has OraSure Technologies' stock performed in 2022?

OraSure Technologies' stock was trading at $8.69 at the beginning of 2022. Since then, OSUR stock has decreased by 67.9% and is now trading at $2.79.
View the best growth stocks for 2022 here
.

When is OraSure Technologies' next earnings date?

OraSure Technologies is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for OraSure Technologies
.

How were OraSure Technologies' earnings last quarter?

OraSure Technologies, Inc. (NASDAQ:OSUR) released its earnings results on Tuesday, May, 10th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.14. The medical instruments supplier had revenue of $67.71 million for the quarter, compared to the consensus estimate of $60.17 million. OraSure Technologies had a negative trailing twelve-month return on equity of 12.15% and a negative net margin of 19.25%. The company's revenue was up 15.6% on a year-over-year basis. During the same quarter last year, the company earned $0.05 EPS.
View OraSure Technologies' earnings history
.

Who are OraSure Technologies' key executives?

OraSure Technologies' management team includes the following people:
  • Mr. Scott Gleason, Sr. VP of Investor Relations & Corp. Communications and Interim CFO (Age 43, Pay $362.92k)
  • Ms. Agnieszka M. Gallagher J.D., Exec. VP, Gen. Counsel, Chief Compliance Officer & Sec. (Age 48, Pay $542.44k)
  • Ms. Kathleen Gallagher Weber, Pres of Molecular Solutions (Age 54, Pay $1.12M)
  • Ms. Carrie Eglinton Manner, Pres, CEO & Director (Age 47)
  • Ms. Michele Marie Miller, Sr. VP, Chief Accounting Officer, Controller & Assistant Sec. (Age 48)
  • Mr. David A. Rappaport C.F.A., CFA, Sr. VP Corp. Devel., Strategy & Integration
  • Amy Steigerwalt, VP of HR
  • Ms. Lisa Nibauer, Pres of Diagnostics (Age 53)

What is Stephen Tang's approval rating as OraSure Technologies' CEO?

2 employees have rated OraSure Technologies CEO Stephen Tang on Glassdoor.com. Stephen Tang has an approval rating of 100% among OraSure Technologies' employees. This puts Stephen Tang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OraSure Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OraSure Technologies investors own include Merit Medical Systems (MMSI), Citigroup (C), Energy Transfer (ET), XOMA (XOMA), Overstock.com (OSTK), Ford Motor (F), Pfizer (PFE), Abbott Laboratories (ABT), Advanced Micro Devices (AMD) and Activision Blizzard (ATVI).

What is OraSure Technologies' stock symbol?

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

Who are OraSure Technologies' major shareholders?

OraSure Technologies' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (18.42%), Bank of America Corp DE (7.79%), Earnest Partners LLC (7.07%), Vanguard Group Inc. (6.78%), State Street Corp (4.57%) and Dimensional Fund Advisors LP (4.27%).
View institutional ownership trends for OraSure Technologies
.

Which major investors are selling OraSure Technologies stock?

OSUR stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Empire Life Investments Inc., Goldman Sachs Group Inc., Simplex Trading LLC, State Street Corp, Jane Street Group LLC, Neuberger Berman Group LLC, and Murphy Pohlad Asset Management LLC.
View insider buying and selling activity for OraSure Technologies
or view top insider-selling stocks.

Which major investors are buying OraSure Technologies stock?

OSUR stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Earnest Partners LLC, Dimensional Fund Advisors LP, Sei Investments Co., Fisher Asset Management LLC, Vanguard Group Inc., Nia Impact Advisors LLC, and Factorial Partners LLC.
View insider buying and selling activity for OraSure Technologies
or or view top insider-buying stocks.

How do I buy shares of OraSure Technologies?

Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OraSure Technologies' stock price today?

One share of OSUR stock can currently be purchased for approximately $2.79.

How much money does OraSure Technologies make?

OraSure Technologies (NASDAQ:OSUR) has a market capitalization of $202.15 million and generates $233.67 million in revenue each year. The medical instruments supplier earns $-23 million in net income (profit) each year or ($0.65) on an earnings per share basis.

How many employees does OraSure Technologies have?

OraSure Technologies employs 785 workers across the globe.

How can I contact OraSure Technologies?

OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The official website for OraSure Technologies is www.orasure.com. The medical instruments supplier can be reached via phone at (610) 882-1820, via email at [email protected], or via fax at 610-882-1830.

This page (NASDAQ:OSUR) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.